Groundbreaking Trial Shows PADN System Benefits Pulmonary Hypertension Patients

Groundbreaking results from the PADN-HF-PH trial, published in The New England Journal of Medicine, demonstrate that the Pulmonary Artery Denervation (PADN) System significantly improves outcomes for patients with pulmonary hypertension associated with left heart disease. The study of 264 patients showed a 51% reduction in clinical worsening risk and sustained improvements in functional capacity. This represents a major advance in treating a complex heart condition.